Does the benefit of optimal MASH treatment depend on a reduction in myosteatosis?
{{output}}
The muscle-liver axis, well known in cirrhosis, is also important in the multi-systemic disease known as metabolic dysfunction-associated steatohepatitis (MASH). The convincing results obtained with a triple peroxisome proliferator-activated receptor (PPAR) ag... ...
